Recent IRadimed News
• Reports record revenue of $17.5 million for the fourth quarter and $65.6 million for the full year of 2023.
• Reports GAAP diluted EPS of $0.36 and non-GAAP diluted EPS of $0.39 for the fourth quarter of 2023.
• Reports GAAP diluted EPS of $1.35 and non-GAAP diluted EPS of $1.48 for the full year of 2023.
• Reports fourth quarter of 2023 operating income of $5.2 million, an increase of 21.3%, compared to the same period in 2022 and full-year operating income of $20.0 million, an increase of 28.2%, compared to the same period in 2022.
Winter Springs, Florida, January 2, 2024 – IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leader in developing innovative Magnetic Resonance Imaging (‘MRI”) compatible medical devices, today announced that the Company will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference.
Iradimed’s CEO, Roger Susi, is scheduled to present on Thursday, January 11, 2024, at 12:00 p.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the “Events and Presentations” section of the Company’s investor website at https://www.iradimed.com/investors/events.
Winter Springs, Florida, December 12, 2023 – IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD) announced today that its Board of Directors approved a special cash dividend of $0.48 per share and the initiation of a regular quarterly dividend on the Company's outstanding common stock. The regular quarterly dividend is $0.15 per share. The special cash dividend and the quarterly dividend are payable on January 12, 2024, to shareholders of record at the close of business on December 22, 2023.
IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) was recently named on Forbes’ latest list of America’s Most Successful Small-Cap Companies for 2024. Iradimed is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.
Reports record revenue of $16.5 million for the third quarter of 2023.
GAAP diluted EPS of $0.40 and non-GAAP diluted EPS of $0.43.
Third quarter operating income of $5.9 million, an increase of 43% compared to the same period in 2022.
Winter Springs, Florida, September 6, 2023 – IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced that the Company will be participating in two upcoming investor conferences.
Reports record revenue of $16.1 million for the second quarter of 2023
GAAP diluted EPS of $0.33 and non-GAAP diluted EPS of $0.36
Operating income was $5.0 million and increased by 19%
Announces third quarter and full year 2023 financial guidance
Winter Springs, Florida, May 10, 2023 – IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), was recently named on Forbes’ latest list of America’s Best Small Companies for 2023. Iradimed is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a nonmagnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.
Reports record revenue of $15.5 million for the first-quarter quarter of 2023
GAAP diluted EPS of $0.27 and non-GAAP diluted EPS of $0.30
Operating income was $4.0 million and increased by 30%
Announces second quarter 2023 financial guidance and increases full-year 2023 financial guidance
• Reports fourth quarter 2022 revenue of $14.9 million, GAAP diluted EPS of $0.29 and non-GAAP diluted EPS of $0.32.
• Reports full-year 2022 revenue of $53.3 million, GAAP diluted EPS of $1.02 and non-GAAP diluted EPS of $1.10.
• The Board of Directors approved a special cash dividend of $1.05 per share. This special cash dividend is payable on February 21, 2023, to shareholders of record at the close of business on February 13, 2023.
• Reports preliminary fourth quarter 2022 revenue of $14.9 million
• Announces full-year and first-quarter 2023 financial guidance
• Revenue was $13.4 million and increased by 23%
• Operating income was $4.1 million and increased 32%
• GAAP diluted EPS was $0.27 and increased by 35%
• Announces fourth quarter 2022 financial guidance
Winter Springs, Florida, October 6, 2022 – IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced the appointment of Hilda Scharen-Guivel to the Iradimed Board of Directors, effective October 4, 2022. Following the appointment of Ms. Scharen-Guivel, the Board will comprise five directors, three of whom are independent.
Reports second quarter 2022 revenue of $12.7 million, GAAP diluted EPS of $0.26 and non-GAAP diluted EPS of $0.26
Announces third quarter 2022 financial guidance
Winter Springs, Florida, July 22, 2022 – IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2022 second quarter financial results before the market opens on Friday, July 29th. IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.
Winter Springs, Florida, April 5, 2022 – IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2022 first quarter financial results before the market opens on Friday, April 29th. IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.
Winter Springs, Florida, February 7, 2022 – IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), announced that its Board of Directors approved a special cash dividend of $1.00 per share on the Company’s outstanding common stock. This special cash dividend is payable on February 24, 2022 to shareholders of record at the close of business on February 17, 2022. The Company is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices. It produces the only known non-magnetic intravenous (“IV”) infusion pump system, and a non-magnetic patient vital signs monitoring system that is designed for use during MRI procedures.